Ticker LaunchUplisting · ELOX
Eloxx Pharmaceuticals, Inc.
Formerly Sevion Therapeutics, Inc.; SENESCO TECHNOLOGIES INC; NAVA LEISURE USA INC
Eloxx Pharmaceuticals, Inc. (ELOX), already reporting to the SEC, moved up to Nasdaq Capital Market on Jun 9, 2026 with an offering at $11.00 per share. Leerink Partners was lead-left underwriter, joined by Guggenheim. Latham & Watkins advised the company and Goodwin Procter advised the underwriters.
Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing small molecule candidates that promote readthrough of premature stop codons caused by nonsense mutations. Its lead candidate, exaluren, is being developed for rare kidney diseases, initially Alport syndrome, and is licensed to Almirall for skin diseases.
- Status
- Uplisting
- Ticker
- ELOX
- Exchange
- Nasdaq Capital Market
- Listed
- Jun 9, 2026
- Price
- $11.00
- Price range
- $10.00–$12.00
- Market cap at IPO price
- $44.4M
- First filed
- Jul 17, 2013
- Underwriters
- Leerink Partners and Guggenheim
- Company counsel
- Latham & Watkins
- Underwriters' counsel
- Goodwin Procter
- Sector
- Biotech & pharma
- Country / state
- MA
More on this listing for subscribers
- Shares offered, over-allotment and shares outstanding after the offering
Every record in the database also has its full filing timeline, a daily-updated calendar, watchlist alerts and Excel export.
Then $99/month or $999/year. Cancel anytime.
Filings
- Registration statement (S-1) first filed Jul 17, 2013
- Latest amendment Jun 4, 2026
- Final prospectus (424B4) Jun 9, 2026
- All filings on EDGAR CIK 1035354